Lazard Capital Upgrades Progenics Pharmaceutical (PGNX) to Buy
More News related to PGNX
- Progenics Announces Third Quarter 2009 Financial Results
- BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals
- Lazard Capital Upgrades Progenics Pharmaceuticals (PGNX) to Buy
- Lazard Capital Upgrades Progenics Pharmaceutical (PGNX) to Buy
- Needham Cuts Progenics (PGNX) to Hold Midday
More News related to Upgrades
- Auriga Reiterates a 'Buy' on McDermott International (MDR); Upstream/Government Story Trumps Quarterly Noise
- Citi Upgrades Chile Stocks to Overweight, Downgrades Colombia Stocks to Neutral
- Baird Maintains a 'Neutral' Rating on Cephalon (CEPH), Reslizumab Mixed Results in EE Sets Back Potential for Upside
- Wedbush Removes McDonald's (MCD) from 'Best Ideas' List; Reiterates Outperform
- Piper Jaffray Maintains an 'Overweight' on Cephalon (CEPH); Buy on Weakness
Lazard Capital upgrades Progenics Pharmaceutical (Nasdaq: PGNX) from Hold to Buy.
To see more analyst ratings on PGNX Click Here.
Related Categories
UpgradesStocks Mentioned
+0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
